RIGEL PHARMS is a pharmaceutical company focused on Oncology, Metabolic. Key products include TAVALISSE.
FDA Novel Drug Designations
(2018-2022)RIGEL PHARMS at a Glance
- Fast trial execution (18 months median completion)
RIGEL PHARMS's Key Drugs
RIGEL PHARMS's core commercial portfolio centers on GAVRETO, TAVALISSE, REZLIDHIA, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
RIGEL PHARMS's Recent FDA Approvals
New NDA/BLA approvals for RIGEL PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
RIGEL PHARMS's Therapeutic Areas
RIGEL PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
RIGEL PHARMS's Top Competitors
RIGEL PHARMS's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
RIGEL PHARMS Pipeline Snapshot
Active clinical trials for RIGEL PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • GAVRETO leads revenue
- • 3 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/6 completed
- • Speed: 18 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges